

Dana-Farber Cancer Institute Researchers Accused of Manipulating Data

Crimson, Jan 12

**Dana-Farber cancer researchers
moving to retract one paper, correct
others in broad investigation of
manipulated data**

STAT, Jan 19



By [Jonathan Wosen](#) and [Angus Chen](#) Jan. 19, 2024

**Dana-Farber expands studies to be
retracted to 6, plus 31 to be corrected
over mishandled data**



By [Angus Chen](#) and [Jonathan Wosen](#) Jan. 22, 2024

**Dana-Farber retracts string of
studies in systematic review of data
integrity**

STAT, Apr 18



By [Angus Chen](#) April 18, 2024

Dana-Farber to Retract 6 Papers, Correct 31 Following Data Manipulation Claims

Crimson, Jan 22

Harvard Teaching Hospital Seeks Retraction of Six Papers by Top Researchers

Dana-Farber Cancer Institute is reviewing more than 50 papers, including work of the hospital's CEO

By [Nidhi Subbaraman](#) [Follow](#)

Updated Jan. 22, 2024 3:32 pm ET

WSJ, Jan 22

Science, Jan 24

Stop Hocusing Your Western Blots, Maybe

24 JAN 2024 • 10:21 AM ET • BY DERE LOWE • 3 MIN READ • COMMENTS

Top Cancer Center Seeks to Retract or Correct Dozens of Studies

A British biologist and blogger discovered faulty data in many studies conducted by top executives of the Dana-Farber Cancer Institute.

NYC, Jan 22

Dana-Farber retractions: meet the blogger who spotted problems in dozens of cancer papers

Nature talks to Sholto David about his process for flagging image manipulation and his tips for scientists under scrutiny.

Nature, Jan 24

p16^{INK4A} Participates in a G₁ Arrest Checkpoint in Response to DNA Damage

GEOFFREY I. SHAPIRO,^{1,2} CHRISTIAN D. EDWARDS,^{1,2} MARK E. EWEN,¹
AND **BARRETT J. ROLLINS**^{1,2*}

*Department of Adult Oncology¹ and Thoracic Oncology Program,² Dana-Farber Cancer Institute,
Harvard Medical School, Boston, Massachusetts 02115*

Received 4 June 1997/Returned for modification 28 July 1997/Accepted 10 October 1997

[SHAPIRO 1998](#)

[AZAB 2009](#)

RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma

Abdel Kareem Azab,¹ Feda Azab,¹ Simona Blotta,¹ Costas M. Pitsillides,² Brian Thompson,² Judith M. Runnels,¹
Aldo M. Roccaro,¹ Hai T. Ngo,¹ Molly R. Melhem,¹ Antonio Sacco,¹ Xiaoying Jia,¹ **Kenneth C. Anderson**,¹
Charles P. Lin,² **Barrett J. Rollins**,¹ and **Irene M. Ghobrial**¹

¹Medical Oncology, Dana-Farber Cancer Institute and ²Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

*Abdel Kareem Azab,^{1,2} *Judith M. Runnels,^{1,2} Costas Pitsillides,² Anne-Sophie Moreau,¹ Feda Azab,¹ Xavier Leleu,¹
Xiaoying Jia,¹ Renee Wright,³ Beatriz Ospina,³ Alicia L. Carlson,² Clemens Alt,² Nicholas Burwick,¹ Aldo M. Roccaro,¹
Hai T. Ngo,¹ Mena Farag,¹ Molly R. Melhem,¹ Antonio Sacco,¹ Nikhil C. Munshi,¹ Teru Hideshima,¹ **Barrett J. Rollins**,¹
Kenneth C. Anderson,¹ Andrew L. Kung,³ †Charles P. Lin,² and †**Irene M. Ghobrial**¹

¹Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; ²Advanced Microscopy Program, Center for Systems Biology and Wellman Center for Photomedicine, Massachusetts General Hospital, Boston; and ³Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston and Harvard Medical School, Boston, MA

[AZAB 2009](#)